ACI’s 7th Annual Summit on Controlled Substances – Regulation, Litigation, and Enforcement

The legal and regulatory landscape for controlled substances is in flux – telehealth prescribing rules have been extended to December 31, 2025, the new “HALT Fentanyl Act” heads to President Trump’s desk, all while recent opioid settlements signal sharper enforcement.  Against this backdrop, the American Conference Institute’s (ACI’s) 7th Annual Summit on Controlled Substances – Regulation, Litigation, and Enforcement is relaunching and is scheduled to take place from January 26-27, 2026 at the Virgin Hotels New York City in New York, NY.  The summit aims to deliver the essential strategies you need to respond, adapt, and lead in the legal and regulatory landscape for controlled substances.

Why You Can’t Miss It:

Hear firsthand from regulators, in-house counsel, compliance leaders, and enforcement specialists. Walk away from tailored sessions that empower you to:

• Decode shifting DOJ & DEA priorities to reduce legal and regulatory exposure
• Prepare for telehealth’s next chapter under the pending Special Registration rule
• Align your SOM programs with new DEA compliance standards
• Manage supply chain and quota risks through smarter strategies
• Stay ahead of the prosecution curve as federal and state enforcement intensifies

What You’ll Gain:

• Forward-looking insights to shape your 2026 legal, compliance, and operations roadmap
• Proven solutions for telemedicine prescribing, enforcement readiness, and enterprise risk
• Trusted expertise from past and current DEA, FDA, DOJ officials, top law firms, and leading in-house teams
• Cross-functional connections spanning pharma, biotech, telehealth, distributors, retail, and government

Hyman, Phelps & McNamara, P.C.’s Andrew J. Hull (and former Assistant U.S. Attorney, United States Attorneys’ Office) will moderate a discussion with the Hon. John Mulrooney, a former DEA Chief Administrative Law Judge (see our previous posts here and here), in a session titled “Perspectives From the Bench: The Ins and Outs of Trying a Diversion Case and Best Practices for Working With Your Outside Counsel.”

FDA Law Blog is a conference media partner.  As such, we can offer our readers a special 10% discount.  The discount code is: D10-999-FDA26.  You can access the conference brochure and sign up for the event here.  We look forward to seeing you at the conference!